Dermicus telemedicine platform was founded in 2010 by MD, PhD Johan Heilborn.
Dr Heilborn identified from his work as Head of Dermatology at the Karolinska Hospital, Sweden, that he could improve patient care and increase efficiency by using emerging mobile applications and platform to improve the quality and speed of skin cancer diagnosis.
Dr Heilborn also recognised that if such a solution was implemented, with strong training and with continuous learning from the start, clinicianswould adopt the new technology. This commitment to easy implementation, training and continuous education remains at the heart of the Dermicus solution today.
The Dermicus platform, mobile application and education program have been developed in close collaboration with Specialists in Dermatology and General Practitioners.
Over the years the product development has been advised by legal and technical resources from Karolinska University Hospital in Stockholm. During 2012 the first beta-version was launched and implemented through a pilot test in several Primary Care centers in Stockholm.
In 2014, Dermicus platform and mobile application were CE-certified as a Class I medical device. During the pilot phase, clinical studies had been performed to prove the effectiveness of increasing patient care quality.
As a result of the successful pilot and clinical studies, the company Gnosco AB was formed, with serial entrepreneur Daniel Eliasson joining as co-owner and CEO.
The focus of Gnosco was to roll-out Dermicus to global healthcare systems and to continue the development to improve patient care quality and support transformational change.
The Gnosco team continue to evolve the Dermicus platform with their Swedish healthcare customers and clinical users. To date, in Sweden, the Dermicus platform has delivered more than 10 000 consultations and maintains more than 40,000 images.
Expansion into other healthcare markets continues, with pilots in the UK and other countries underway in 2018.